+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Bevacizumab"

From
From
Ovarian Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Ovarian Cancer Drugs - Global Strategic Business Report

  • Report
  • March 2025
  • 250 Pages
  • Global
From
From
Liver Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • February 2025
  • 277 Pages
  • Global
From
Intestine Cancer Therapeutics Market Report 2025 - Product Thumbnail Image

Intestine Cancer Therapeutics Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Cervical Cancer Drugs Market Report 2025 - Product Thumbnail Image

Cervical Cancer Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Colorectal Cancer Drugs Market Report 2025 - Product Thumbnail Image

Colorectal Cancer Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Bevacizumab Biosimilars Market Report 2025 - Product Thumbnail Image

Bevacizumab Biosimilars Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Immuno-Oncology Drugs Market Report 2025 - Product Thumbnail Image

Immuno-Oncology Drugs Market Report 2025

  • Report
  • March 2025
  • 250 Pages
  • Global
From
Soft Tissue Sarcoma Market Report 2025 - Product Thumbnail Image

Soft Tissue Sarcoma Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Lung Cancer Therapeutics Market 2025-2033 - Product Thumbnail Image

Lung Cancer Therapeutics Market 2025-2033

  • Report
  • March 2025
  • 140 Pages
  • Global
From
From
Loading Indicator

Bevacizumab is a monoclonal antibody used in the treatment of various types of cancer. It is used in combination with other drugs to treat metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and metastatic breast cancer. Bevacizumab works by inhibiting the growth of new blood vessels, which can help slow the growth of tumors. It is administered intravenously and is typically given in combination with other chemotherapy drugs. Bevacizumab is a widely used drug in the oncology market, and is one of the most prescribed drugs for cancer treatment. It is used in combination with other drugs to treat a variety of cancers, and is often used in combination with chemotherapy. Bevacizumab has been shown to be effective in treating certain types of cancer, and is generally well tolerated. Some companies in the Bevacizumab market include Genentech, Roche, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more